SCHEMBL11937232

SCHEMBL11937232

COc1ccc(-c2coc3ccc(C(C)(C)C)cc3c2=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.59
KLK7 P49862 1/20 0.59
MAPT P10636 9/20 0.58
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
SMN1; SMN2 Q16637 7/20 0.58
ALDH1A1 P00352 6/20 0.58
CYP3A4 P08684 5/20 0.58
KDM4E B2RXH2 4/20 0.58
TP53 P04637 4/20 0.58
HPGD P15428 3/20 0.58
HSD17B10 Q99714 3/20 0.58
CYP2D6 P10635 3/20 0.58
CYP2C9 P11712 3/20 0.58
CYP2C19 P33261 3/20 0.58
MAOA P21397 2/20 0.58
MAOB P27338 2/20 0.58
CYP1B1 Q16678 2/20 0.58
HDAC6 Q9UBN7 2/20 0.58
BCL2 P10415 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640433 0.86 RAB9A (0.67) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL28172130 0.86 RAB9A (0.67) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL11937231 0.84 ALOX15 (0.45) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL11942187 0.80 RAB9A (0.59) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL30605366 0.79 TERT (0.69) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL29089301 0.79 TERT (0.69) RAB9AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7030328 0.79 RAB9A (0.81) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL29068825 0.79 MAPT (0.80) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL30573375 0.79 RAB9A (0.81) RAB9AKLK7MAPTMEN1KMT2A
SCHEMBL571576 0.78 XDH (0.84) RAB9AKLK7MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227456-B2 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-07-24 US disclosed
US-7879835-B2 treating osteoporosis, comprising administering drugs such as (E)-methyl 2-(2-((4-octylphenoxy)methyl)-3-methoxyacrylate, which inhibit osteoclast formation or resorption activity; side effect reduction KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-02-01 US disclosed
US-20100256367-A1 Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-10-07 US disclosed
US-20080280901-A1 Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256367-A1 Pharmaceutical Composition For Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyactylate Derivatives ARSA, BMP2, BMP1 RAB9A 3323/4885KLK7 3635/4885MAPT 2797/4885
US-20080280901-A1 Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives CYP24A1, SOST, ACP3 RAB9A 2892/4885KLK7 3012/4885MAPT 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.